{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"WO_2006_094705_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"151-203-782-179-960"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":22872,"type":"PATENT","title":"Citing Free Univ Berlin publications","description":"Patent documents citing scholarly work of Free Univ Berlin","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":28928,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:44:55Z","updated":"2017-08-07T05:44:55Z","lastEventDate":"2017-08-07T05:44:55Z"},{"id":210483,"type":"PATENT","title":"Novartis Patents","description":"","access":"OPEN_ACCESS","displayAvatar":true,"avatar":{"id":4163,"key":"lens/avatar/7bf4d0b2-758a-4ce4-830d-a93cfcac7a2d"},"attested":false,"itemCount":97883,"tags":[],"user":{"id":150912620,"username":"Aaron","firstName":"Aaron","lastName":"Ballagh","created":"2016-04-19T11:31:15.000Z","displayName":"Aaron Ballagh","profilePictureKey":"lens/avatar/4c7ebafd-a645-4928-80f0-86226d3aba10","avatar":{"id":1420,"key":"lens/avatar/4c7ebafd-a645-4928-80f0-86226d3aba10"},"preferences":"{\"fontSize\":100,\"beta\":true,\"usage\":\"professional\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[{"id":49501,"title":"Novartis Patent Owners","queryId":"3fdd12cb-c9bf-46b8-b6e9-a26ad1a9c4db"},{"id":49500,"title":"Novartis Patent Applicants","queryId":"1dca7c18-61f7-4a1a-9cf9-157183078724"}],"created":"2023-06-22T04:16:27Z","updated":"2024-03-28T02:01:53Z","lastEventDate":"2024-03-28T02:01:53Z"}],"notes":[],"inventorships":[],"privateCollections":[],"publicCollections":[{"id":22872,"type":"PATENT","title":"Citing Free Univ Berlin publications","description":"Patent documents citing scholarly work of Free Univ Berlin","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":28928,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:44:55Z","updated":"2017-08-07T05:44:55Z","lastEventDate":"2017-08-07T05:44:55Z"},{"id":210483,"type":"PATENT","title":"Novartis Patents","description":"","access":"OPEN_ACCESS","displayAvatar":true,"avatar":{"id":4163,"key":"lens/avatar/7bf4d0b2-758a-4ce4-830d-a93cfcac7a2d"},"attested":false,"itemCount":97883,"tags":[],"user":{"id":150912620,"username":"Aaron","firstName":"Aaron","lastName":"Ballagh","created":"2016-04-19T11:31:15.000Z","displayName":"Aaron Ballagh","profilePictureKey":"lens/avatar/4c7ebafd-a645-4928-80f0-86226d3aba10","avatar":{"id":1420,"key":"lens/avatar/4c7ebafd-a645-4928-80f0-86226d3aba10"},"preferences":"{\"fontSize\":100,\"beta\":true,\"usage\":\"professional\"}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[{"id":49501,"title":"Novartis Patent Owners","queryId":"3fdd12cb-c9bf-46b8-b6e9-a26ad1a9c4db"},{"id":49500,"title":"Novartis Patent Applicants","queryId":"1dca7c18-61f7-4a1a-9cf9-157183078724"}],"created":"2023-06-22T04:16:27Z","updated":"2024-03-28T02:01:53Z","lastEventDate":"2024-03-28T02:01:53Z"}],"privateNotes":[],"landscapeCollections":[],"landscapeNotes":[]},"document":{"record_lens_id":"151-203-782-179-960","lens_id":["151-203-782-179-960","053-813-834-126-664"],"doc_key":"WO_2006094705_A1_20060914","created":"2016-01-15T14:11:09.002","docdb_id":281045453,"lens_internal":{"earliest_lens_id_created_time":"2016-01-15T14:11:09.002","last_modified":"2024-03-25T22:23:25.65","legacy_pub_key":"WO_2006_094705_A1","has_doc_lang":true,"has_biblio_lang":true,"has_all_title_lang":true,"has_all_abstract_lang":true,"has_all_claims_lang":true,"has_description_lang":true},"jurisdiction":"WO","doc_number":"2006094705","kind":"A1","date_published":"2006-09-14","year_published":2006,"ids":["WO_2006_094705_A1","151-203-782-179-960","053-813-834-126-664","WO_2006094705_A1_20060914","WO","2006094705","A1","WO2006094705A1","WO2006094705","2006094705A1"],"lang":"en","publication_type":"PATENT_APPLICATION","application_reference":{"jurisdiction":"EP","doc_number":"2006001905","kind":"W","date":"2006-03-02"},"priority_claim":[{"jurisdiction":"GB","doc_number":"0504544","kind":"A","date":"2005-03-04"}],"priority_claim.source":"DOCDB","earliest_priority_claim_date":"2005-03-04","title":{"en":[{"text":"OPHTHALMIC USES OF S1P RECEPTOR MODULATORS","lang":"en","source":"DOCDB","data_format":"DOCDBA"}],"fr":[{"text":"UTILISATIONS OPHTALMIQUES DE MODULATEURS DE RECEPTEUR S1P","lang":"fr","source":"DOCDB","data_format":"DOCDBA"}]},"title_lang":["en","fr"],"has_title":true,"applicant":[{"name":"NOVARTIS AG","residence":"CH","sequence":1,"app_type":"applicant"},{"name":"NOVARTIS PHARMA GMBH","residence":"AT","sequence":2,"app_type":"applicant"},{"name":"LAMBROU GEORGE N","residence":"FR","sequence":3,"app_type":"applicant"},{"name":"LATOUR ELISABETH JEANNE","residence":"FR","sequence":4,"app_type":"applicant"}],"applicant_count":4,"has_applicant":true,"inventor":[{"name":"LAMBROU GEORGE N","residence":"FR","sequence":1},{"name":"LATOUR ELISABETH JEANNE","residence":"FR","sequence":2}],"inventor_count":2,"has_inventor":true,"agent":[{"name":"THOMSEN, Peter","address":"Novartis AG, Corporate Intellectual Property, CH-4002 Basel","country":"CH","sequence":1}],"agent_count":1,"has_agent":true,"owner":[],"owner_count":0,"owner_all":[],"owner_all_count":0,"has_owner":false,"has_examiner":false,"class_ipcr":[{"symbol":"A61K31/13","version_indicator":"2006-01-01","class_symbol_position":"F","class_value":"I","action_date":"2006-09-14","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":1},{"symbol":"A61P27/02","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2006-09-14","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":2}],"class_ipcr.first_symbol":"A61K31/13","class_ipcr.later_symbol":["A61P27/02"],"class_ipcr.inv_symbol":["A61K31/13","A61P27/02"],"class_ipcr.add_symbol":[],"class_ipcr.source":"DOCDB","class_cpc":[{"symbol":"A61K31/13","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2016-09-01","class_status":"B","class_data_source":"H","generating_office":"KR","sequence":1},{"symbol":"A61K31/13","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2019-08-22","class_status":"B","class_data_source":"H","generating_office":"US","sequence":2},{"symbol":"A61K31/13","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":3},{"symbol":"A61K31/135","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2016-09-01","class_status":"B","class_data_source":"H","generating_office":"KR","sequence":4},{"symbol":"A61K31/662","version_indicator":"2013-01-01","class_symbol_position":"L","class_value":"I","action_date":"2016-09-01","class_status":"B","class_data_source":"H","generating_office":"KR","sequence":5},{"symbol":"A61P9/10","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-31","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":6},{"symbol":"A61P25/02","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-23","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":7},{"symbol":"A61P27/02","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-24","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":8},{"symbol":"A61P31/02","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-27","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":9}],"class_cpc_cset":[],"class_cpc.first_symbol":"A61K31/13","class_cpc.later_symbol":["A61K31/135","A61K31/662","A61P9/10","A61P25/02","A61P27/02","A61P31/02"],"class_cpc.inv_symbol":["A61K31/13","A61K31/13","A61K31/13","A61K31/135","A61K31/662","A61P9/10","A61P25/02","A61P27/02","A61P31/02"],"class_cpc.add_symbol":[],"class_cpc.source":"DOCDB","class_national":[],"class_national.later_symbol":[],"reference_cited":[{"patent":{"num":1,"document_id":{"jurisdiction":"WO","doc_number":"2004103306","kind":"A2","date":"2004-12-02","name":"IRM LLC [US], et al"},"lens_id":"003-188-249-031-23X","srep_office":"EP","category":["D","X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":1}},{"patent":{"num":2,"document_id":{"jurisdiction":"WO","doc_number":"0218395","kind":"A1","date":"2002-03-07","name":"MERCK & CO INC [US], et al"},"lens_id":"162-973-877-562-241","srep_office":"EP","category":["D","X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":2}},{"patent":{"num":3,"document_id":{"jurisdiction":"WO","doc_number":"2004096757","kind":"A1","date":"2004-11-11","name":"NOVARTIS AG [CH], et al"},"lens_id":"024-414-281-873-191","srep_office":"EP","category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":3}},{"patent":{"num":4,"document_id":{"jurisdiction":"WO","doc_number":"2004110979","kind":"A2","date":"2004-12-23","name":"NOVARTIS AG [CH], et al"},"lens_id":"012-589-188-480-966","srep_office":"EP","category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":4}},{"patent":{"num":5,"document_id":{"jurisdiction":"WO","doc_number":"03061567","kind":"A2","date":"2003-07-31","name":"MERCK & CO INC [US], et al"},"srep_office":"EP","category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":5}},{"patent":{"num":6,"document_id":{"jurisdiction":"WO","doc_number":"2005014525","kind":"A2","date":"2005-02-17","name":"MITSUBISHI PHARMA CORP [JP], et al"},"lens_id":"166-295-059-476-531","srep_office":"EP","category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":6}},{"npl":{"num":1,"text":"ER-PING ETAL: \"Significant porlongation od orthotopic cornela graft survival in FTY720 treated mice\", TRANSPLANTATION, vol. 76, no. 10, 2003 - 2003, pages 1511 - 1513, XP002382821","npl_type":"s","xp_number":"002382821","external_id":["10.1097/01.tp.0000086344.04487.4f","14657695"],"record_lens_id":"014-230-505-299-565","lens_id":["160-750-617-877-377","014-230-505-299-565","187-509-453-148-686"],"sequence":7,"category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"srep_office":"EP"}},{"npl":{"num":2,"text":"KUROSE ETAL: \"Effects of FTY720 a novel immunosppressant on Experimental Autoimmune Uveorentitis in rats.\", EXP. EYE. RES, vol. 70, no. 7, 2000 - 2000, pages 7 - 15, XP002382822","npl_type":"s","xp_number":"002382822","external_id":["10644416","10.1006/exer.1999.0777"],"record_lens_id":"076-375-844-837-854","lens_id":["188-109-857-731-855","076-375-844-837-854","156-234-279-184-467"],"sequence":8,"category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"srep_office":"EP"}},{"patent":{"num":7,"document_id":{"jurisdiction":"US","doc_number":"2004147490","kind":"A1","date":"2004-07-29","name":"ALBERT RAINER [CH], et al"},"lens_id":"111-386-511-053-470","srep_office":"EP","category":["X"],"us_category":[],"cited_phase":"ISR","cited_date":"2006-07-04","rel_claims":[],"sequence":9}}],"reference_cited.source":"DOCDB","reference_cited.patent_count":7,"cites_patent":true,"reference_cited.npl_count":2,"reference_cited.npl_resolved_count":2,"cites_npl":true,"cites_resolved_npl":true,"cited_by":{"patent_count":15,"patent":[{"lens_id":"141-536-820-331-576","document_id":{"jurisdiction":"RU","doc_number":"2487703","kind":"C2"}},{"lens_id":"026-855-044-573-722","document_id":{"jurisdiction":"WO","doc_number":"2008154470","kind":"A1"}},{"lens_id":"130-956-992-954-720","document_id":{"jurisdiction":"JP","doc_number":"2013166762","kind":"A"}},{"lens_id":"192-875-466-843-785","document_id":{"jurisdiction":"WO","doc_number":"2007028821","kind":"A3"}},{"lens_id":"073-282-767-937-306","document_id":{"jurisdiction":"CN","doc_number":"110548011","kind":"A"}},{"lens_id":"070-994-308-338-466","document_id":{"jurisdiction":"EP","doc_number":"1923058","kind":"A1"}},{"lens_id":"012-460-163-165-049","document_id":{"jurisdiction":"EP","doc_number":"3747471","kind":"A4"}},{"lens_id":"125-863-261-380-221","document_id":{"jurisdiction":"US","doc_number":"9265754","kind":"B2"}},{"lens_id":"074-477-308-605-624","document_id":{"jurisdiction":"JP","doc_number":"2010504364","kind":"A"}},{"lens_id":"095-033-391-577-162","document_id":{"jurisdiction":"CN","doc_number":"102579387","kind":"A"}},{"lens_id":"147-506-489-770-413","document_id":{"jurisdiction":"EP","doc_number":"1923054","kind":"A1"}},{"lens_id":"012-364-325-072-217","document_id":{"jurisdiction":"US","doc_number":"9399066","kind":"B2"}},{"lens_id":"132-130-045-426-710","document_id":{"jurisdiction":"WO","doc_number":"2019151470","kind":"A1"}},{"lens_id":"003-031-465-622-960","document_id":{"jurisdiction":"JP","doc_number":"2015078198","kind":"A"}},{"lens_id":"177-162-489-243-658","document_id":{"jurisdiction":"WO","doc_number":"2008037421","kind":"A3"}}]},"cited_by_patent":true,"family":{"simple":{"size":21,"id":184435925,"member":[{"lens_id":"148-823-469-474-604","document_id":{"jurisdiction":"EP","doc_number":"2216019","kind":"A2","date":"2010-08-11"}},{"lens_id":"186-355-824-736-132","document_id":{"jurisdiction":"EP","doc_number":"1861081","kind":"A1","date":"2007-12-05"}},{"lens_id":"092-733-550-726-427","document_id":{"jurisdiction":"AU","doc_number":"2010202185","kind":"B2","date":"2012-06-14"}},{"lens_id":"108-643-943-085-931","document_id":{"jurisdiction":"BR","doc_number":"PI0609258","kind":"A2","date":"2010-03-09"}},{"lens_id":"186-690-802-444-807","document_id":{"jurisdiction":"KR","doc_number":"20070108216","kind":"A","date":"2007-11-08"}},{"lens_id":"014-849-002-252-908","document_id":{"jurisdiction":"CN","doc_number":"101132784","kind":"A","date":"2008-02-27"}},{"lens_id":"083-144-034-906-446","document_id":{"jurisdiction":"US","doc_number":"20110313033","kind":"A1","date":"2011-12-22"}},{"lens_id":"040-033-887-707-113","document_id":{"jurisdiction":"CA","doc_number":"2598527","kind":"A1","date":"2006-09-14"}},{"lens_id":"027-434-907-521-962","document_id":{"jurisdiction":"US","doc_number":"20080207739","kind":"A1","date":"2008-08-28"}},{"lens_id":"087-650-708-670-79X","document_id":{"jurisdiction":"RU","doc_number":"2497513","kind":"C2","date":"2013-11-10"}},{"lens_id":"144-357-959-870-430","document_id":{"jurisdiction":"RU","doc_number":"2007136602","kind":"A","date":"2009-04-10"}},{"lens_id":"174-103-009-403-554","document_id":{"jurisdiction":"GB","doc_number":"0504544","kind":"D0","date":"2005-04-13"}},{"lens_id":"058-163-583-142-837","document_id":{"jurisdiction":"JP","doc_number":"2008531632","kind":"A","date":"2008-08-14"}},{"lens_id":"007-307-747-509-288","document_id":{"jurisdiction":"RU","doc_number":"2011115499","kind":"A","date":"2012-10-27"}},{"lens_id":"052-054-896-061-674","document_id":{"jurisdiction":"MX","doc_number":"2007010752","kind":"A","date":"2007-09-12"}},{"lens_id":"141-804-162-096-540","document_id":{"jurisdiction":"EP","doc_number":"2216019","kind":"A3","date":"2010-11-17"}},{"lens_id":"048-081-838-948-604","document_id":{"jurisdiction":"AU","doc_number":"2006222266","kind":"A1","date":"2006-09-14"}},{"lens_id":"002-888-177-604-537","document_id":{"jurisdiction":"AU","doc_number":"2010202185","kind":"A1","date":"2010-06-17"}},{"lens_id":"151-203-782-179-960","document_id":{"jurisdiction":"WO","doc_number":"2006094705","kind":"A1","date":"2006-09-14"}},{"lens_id":"172-052-854-155-383","document_id":{"jurisdiction":"JP","doc_number":"2013063991","kind":"A","date":"2013-04-11"}},{"lens_id":"005-925-124-261-365","document_id":{"jurisdiction":"US","doc_number":"20130065954","kind":"A1","date":"2013-03-14"}}]},"extended":{"size":21,"id":184430584,"member":[{"lens_id":"148-823-469-474-604","document_id":{"jurisdiction":"EP","doc_number":"2216019","kind":"A2","date":"2010-08-11"}},{"lens_id":"186-355-824-736-132","document_id":{"jurisdiction":"EP","doc_number":"1861081","kind":"A1","date":"2007-12-05"}},{"lens_id":"092-733-550-726-427","document_id":{"jurisdiction":"AU","doc_number":"2010202185","kind":"B2","date":"2012-06-14"}},{"lens_id":"108-643-943-085-931","document_id":{"jurisdiction":"BR","doc_number":"PI0609258","kind":"A2","date":"2010-03-09"}},{"lens_id":"186-690-802-444-807","document_id":{"jurisdiction":"KR","doc_number":"20070108216","kind":"A","date":"2007-11-08"}},{"lens_id":"014-849-002-252-908","document_id":{"jurisdiction":"CN","doc_number":"101132784","kind":"A","date":"2008-02-27"}},{"lens_id":"083-144-034-906-446","document_id":{"jurisdiction":"US","doc_number":"20110313033","kind":"A1","date":"2011-12-22"}},{"lens_id":"040-033-887-707-113","document_id":{"jurisdiction":"CA","doc_number":"2598527","kind":"A1","date":"2006-09-14"}},{"lens_id":"027-434-907-521-962","document_id":{"jurisdiction":"US","doc_number":"20080207739","kind":"A1","date":"2008-08-28"}},{"lens_id":"087-650-708-670-79X","document_id":{"jurisdiction":"RU","doc_number":"2497513","kind":"C2","date":"2013-11-10"}},{"lens_id":"144-357-959-870-430","document_id":{"jurisdiction":"RU","doc_number":"2007136602","kind":"A","date":"2009-04-10"}},{"lens_id":"174-103-009-403-554","document_id":{"jurisdiction":"GB","doc_number":"0504544","kind":"D0","date":"2005-04-13"}},{"lens_id":"058-163-583-142-837","document_id":{"jurisdiction":"JP","doc_number":"2008531632","kind":"A","date":"2008-08-14"}},{"lens_id":"007-307-747-509-288","document_id":{"jurisdiction":"RU","doc_number":"2011115499","kind":"A","date":"2012-10-27"}},{"lens_id":"052-054-896-061-674","document_id":{"jurisdiction":"MX","doc_number":"2007010752","kind":"A","date":"2007-09-12"}},{"lens_id":"141-804-162-096-540","document_id":{"jurisdiction":"EP","doc_number":"2216019","kind":"A3","date":"2010-11-17"}},{"lens_id":"048-081-838-948-604","document_id":{"jurisdiction":"AU","doc_number":"2006222266","kind":"A1","date":"2006-09-14"}},{"lens_id":"002-888-177-604-537","document_id":{"jurisdiction":"AU","doc_number":"2010202185","kind":"A1","date":"2010-06-17"}},{"lens_id":"151-203-782-179-960","document_id":{"jurisdiction":"WO","doc_number":"2006094705","kind":"A1","date":"2006-09-14"}},{"lens_id":"172-052-854-155-383","document_id":{"jurisdiction":"JP","doc_number":"2013063991","kind":"A","date":"2013-04-11"}},{"lens_id":"005-925-124-261-365","document_id":{"jurisdiction":"US","doc_number":"20130065954","kind":"A1","date":"2013-03-14"}}]}},"has_sequence":false,"legal_status":{"ipr_type":"patent for invention","granted":false,"earliest_filing_date":"2006-03-02","has_disclaimer":false,"patent_status":"PENDING","publication_count":1,"has_spc":false,"has_grant_event":false,"has_entry_into_national_phase":true},"abstract":{"en":[{"text":"The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder.","lang":"en","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}],"fr":[{"text":"La présente invention a trait à l'utilisation d'un agoniste de récepteur S1P dans la fabrication d'un médicament pour le traitement d'un trouble oculaire.","lang":"fr","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}]},"abstract_lang":["en","fr"],"has_abstract":true,"claim":{"en":[{"text":"CLAIMS 1. Use of an S1 P receptor agαπϊst in the manufacture of a medicament for the treatment of an ocular disorder. 2. Method to treat an ocular disorder which is treatable by an S1P receptor agonist, said method comprising the administration of an effective amount of an S1P receptor agonist to a subject suffering from said ocular disorder. 3. A method, or use according to any preceding claims, wherein said ocular disorder is selected from the group of ischemic retinopathies in general, anterior ischemic optic neuropathy, all forms of optic neuritis, age-related macular degeneration (AMD), in its dry forms (dry AWlD) and wet forms (wet AMD), diabetic retinopathy, diabetic macular edema (DME), prolfferative diabetic retinopathy (PDR), cystoid macular edema (CME), retinal detachment, retinitis pigmentosa (RP), Stargardt's disease, Best's vitelliform retinal degeneration, Leber's congenital amaurosis and cither hereditary retinal degenerations, pathologic myopia, retinopathy of prematurity.and Leber's hereditary optic neuropathy, the after effects of corneal transplants tϊαn or of refractive corneal surgery, keratoconjunctivitis sicca (KCS) or dry eye and herpes keratitis. 4. A method, or use according to any preceding claims, wherein the 531 P receptor agonist is or comprises a group of formula X (X) wherein Z is H, C 1-8 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, phenyl, phenyl substituted by OH, G 1-5 alkyl substituted by 1 to 3 substitueπts selected from the group consisting αf halogen, C 3 -8 cycloalkyl, phenyl and phenyl substituted by OH, or CH 2 -R 42 wherein R 42 is OH, acyloxy or a residue of formula (a) (a) wherein Z 1 is a direct bond or O, praferably O; each of R 52 and R 62 , independently, is H, or C 1-4 alkyl optionally substituted by 1 , 2 or 3 halogen atoms; R 12 is OH, acyloxy or a residue of formula (a); and each of R 22 and R 32 independently, is H, C 1-4 alkyl oracyl, and wherein the group of formula X is a functional group attached as a terminal group to a moiety which may be hydrophllic or lipophilic and comprise one or more aliphatic, alicycllc, aromatic and/or heterocyclic residues, to the extent that the resulting molecule wherein at least one of Z and R 12 is or comprises a residue of formula (a), signals as an agonist at one of more sphiπgosιne-1 -phosphate receptor; in free form or in a pharmaceutically acceptable salt form, as solvate or hydrate thereof. 5 A method, or a use according to claim 4 wherein the S1 P receptcr agonist is 2- amino-2-[2-(4-octy|ρhenyl) ethyl]propane-1,3-diol, Compound B or C 1 (2R)-2-amino- 4-[3-(4-cyclohexy(oxybuty|)-bθnzotb]thien-6-yl] ' 2-methyIbutan-1-ol, or a compound of formula IX as defined hereinbefore wherein X f is S or O, R 1f is benzyloxy, R 2f , R 1f and R 5f , are each H, R 3f is Cl and n f is 2, in free form or in a pharmaceutically acceptable salt form. 6 A method, or a use according to according to any of the preceding claims, wherein the S1P receptor agonist is 2-amino-2-i2-(4-octylpheπyI) ethyl]pnapaπe-1 ,3-dϊol (compound A) in free form or in a pharmaceutically acceptable salt form. 7 A method, or a use according to according to any of the preceding claims, wherein said S1P receptor agonist is administered topically in or around tire eye. 8 A method, or a use according to according to any of the preceding claims, wherein said S1 P receptor agonist is or comprises a group of formula (I): wherein R 1 is a straight- or branched (C 12-22 )chain which may have in the chain a bond or a hetero atom selected from a double bond, a triple bond, O, S, NRe, wherein R 6 is H, alkyl, araikyl, acyl or alkoxycarbonyl, and carbonyl, and/or which may have as a substituent alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylarnino, alkoxycarbonyl, alkoxycarbαnylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxyϊmino, hydroxy or carboxy; or R 7 is a pheπylalkyl wherein alky! is a straight- or branched (C 6-20 )carbon chain; or a phenylalkyl wherein alkyl is a straight- or branched (C 1 -30 )carbαn chain wherein said phenylalky! is substituted by a straight- or branched (C 6-20 )carbon chain optionally substituted by halogen, a straight- or branched (C 6-20 )alkoxy chain optionally substitued by halogen, a straight- or branched (C 6-20 )alkenyloxy, phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl, cycloalkylalkyl substituted by C 6-20 alkyl, hetεroarylalkyl substituted by C 6-20 alkyl, heterocyclic C 6-20 alkyl or heterocyclic alkyl substituted by C 2-20 alky!, and wherein the alkyl moiety may have In the carbon chain, a bond or a heteroatcrn selected from a double bond, a triple bond, O, S, sulfinyl, sutfonyl, or NR 6 , wherein R 6 is as defined above, and as a substituent alkoxy, alkenyloxy, alkyπylαxy, aralkylox/, acyJ, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbαπylaminα, acyloxy, alkylcarbamoyl, nltro. halogen, amino, hydroxy or carboxy, and each of R 2 , R 3 , R 4 and R 5 , independently, is H, C 1-4 alkyl or acyl ; or a pharmacologically acceptable salt, solvate or hydrate thereof. 9 A method, or use according to any preceding claims, wherein said ocular disorder is age-related macular degeneration (AMD), in its dry forms (dry AMD) and wet forms (wet AMD).","lang":"en","source":"WIPO_FULLTEXT","data_format":"ORIGINAL"}]},"claim_lang":["en"],"has_claim":true,"description":{"en":{"text":"Ophthalmic uses of S1P receptor modulators The present invention relates to the use of a an S1P receptor agonist in the manufacture of a medicament for the treatment of ocular disorders. Ocular disorders which may be treated according to this invention include typically an ocular disease and disorder which may directly or indirectly involve the degeneration of retinal or corneal cells, in particular by apoptosis. Ocular disorders, as used herein, include ischemic retinopathies in general, anterior ischemic optic neuropathy, all forms of optic neuritis, age- related macular degeneration (AMD), in its dry forms (dry AMD) and wet forms (wet AMD), diabetic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), cystoid macular edema (CME), retinal detachment, retinitis pigmentosa (RP), Stargardt's disease, Best's vitelliform retinal degeneration, Leber's congenital amaurosis and other hereditary retinal degenerations, pathologic myopia, retinopathy of prematurity, and Leber's hereditary optic neuropathy, the after effects of corneal transplantation or of refractive corneal surgery, keratoconjunctivitis sicca (KCS) or dry eye and herpes keratitis. Preferably, said ocular disorders are selected from: Dry AMD, wet AMD, diabetic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinitis pigmentosa (RP), and keratoconjunctivits sicca (KCS), and even more preferably, said ocular disorders are selected from: Dry AMD, wet AMD, DME and PDR. Also preferably said ocular disorder is PDR. Also preferably said ocular disorder is DME. Also preferably said ocular disorder is keratoconjunctivits sicca (KCS). Highly preferably, said ocular disorders are selected from dry AMD and wet AMD. In the present description the terms \"treatment\" or \"treat\" refer to both prophylactic or preventive treatment as well as curative or disease-modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. S1 P receptor agonists are compounds which signal as agonists at one or more sphingosine- 1 phosphate receptors, e.g. S1P1 to S1P8. Agonist binding to a S1P receptor may e.g. result in dissociation of intracellular heterotrimeric G-proteins into Gα-GTP and Gβγ-GTP, and/or increased phosphorylation of the agonist-occupied receptor and activation of downstream signaling pathways/kinases. S1 P receptor agonists are typically sphingosine analogues, such as 2-substituted 2-amino- propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X (X) wherein Z is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, phenyl substituted by OH, Ci -6 alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C 3-8 cycloalkyl, phenyl and phenyl substituted by OH, or CH 2 -R 4z wherein R 4z is OH, acyloxy or a residue of formula (a) (a) wherein Z 1 is a direct bond or O, preferably O; each of R 5z and R 6z , independently, is H, or C 1-4 alkyl optionally substituted by 1 , 2 or 3 halogen atoms; Riz is OH, acyloxy or a residue of formula (a); and each of R 2z and R 3z independently, is H, C 1-4 alkyl or acyl. Group of formula X is a functional group attached as a terminal group to a moiety which may be hydrophilic or lipophilic and comprise one or more aliphatic, alicyclic, aromatic and/or heterocyclic residues, to the extent that the resulting molecule wherein at least one of Z and R 1z is or comprises a residue of formula (a), signals as an agonist at one of more sphingosine-1 -phosphate receptor. Examples of preferred S1P receptor agonists are, for example: - Compounds as disclosed in EP627406A1, e.g. a compound of formula I wherein R 1 is a straight- or branched (C 12-22 )chain - which may have in the chain a bond or a hetero atom selected from a double bond, a triple bond, O 1 S, NR 6 , wherein R 6 is H, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, and/or - which may have as a substituent alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxyimino, hydroxy or carboxy; or R 1 is - a phenylalkyl wherein alkyl is a straight- or branched (C 6-20 )carbon chain; or - a phenylalkyl wherein alkyl is a straight- or branched (C 1-30 )carbon chain wherein said phenylalkyl is substituted by - a straight- or branched (C 6-20 )carbon chain optionally substituted by halogen, - a straight- or branched (C 6-20 )alkoxy chain optionally substitued by halogen, - a straight- or branched (C 6-20 )alkenyloxy, - phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl, - cycloalkylalkyl substituted by C 6-20 alkyl, - heteroarylalkyl substituted by C 6-20 alkyl, - heterocyclic C 6-20 alkyl or - heterocyclic alkyl substituted by C 2-20 alkyl, and wherein the alkyl moiety may have - in the carbon chain, a bond or a heteroatom selected from a double bond, a triple bond, O, S, sulfinyl, sulfonyl, or NR 6 , wherein R 6 is as defined above, and - as a substituent alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy or carboxy, and each of R 2 , R3, R 4 and R 5 , independently, is H, C 1-4 alkyl or acyl or a pharmacologically acceptable salt, solvate or hydrate thereof; - Compounds as disclosed in EP 1002792A1, e.g. a compound of formula Il wherein m is 1 to 9 and each of R' 2 , R' 3 , R' 4 and R' 5 , independently, is H, alkyl or acyl, or a pharmacologically acceptable salt, solvate or hydrate thereof; - Compounds as disclosed in EP0778263 A1, e.g. a compound of formula III wherein W is H; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; unsubstituted or by OH substituted phenyl; R\" 4 O(CH 2 ) n ; or C 1-4 alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C 3-8 cycloalkyl, phenyl and phenyl substituted by OH; X is H or unsubstituted or substituted straight chain alkyl having a number p of carbon atoms or unsubstituted or substituted straight chain alkoxy having a number (p-1) of carbon atoms, e.g. substituted by 1 to 3 substitutents selected from the group consisting of C 1-6 alkyl, OH, C 1 ^aIkOXy, acyloxy, amino, C 1-6 alkylamino, acylamino, oxo, haloC 1-6 alkyl, halogen, unsubstituted phenyl and phenyl substituted by 1 to 3 substituents selected from the group consisting of C 1-6 alkyl, OH, C 1-6 alkoxy, acyl, acyloxy, amino, C 1-6 alkylamino, acylamino, halo C 1-6 alkyl and halogen; Y is H, C 1-6 alkyl, OH, C 1-6 alkoxy, acyl, acyloxy, amino, C 1- 6 alkylamino, acylamino, haloC 1-6 alkyl or halogen, Z 2 is a single bond or a straight chain alkylene having a number or carbon atoms of q, each of p and q, independently, is an integer of 1 to 20, with the proviso of 6
is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkylthio, carboxyl, lower alkoxycarbonyl, hydroxy, lower aliphatic acyl, amino, mono-lower alkylamino, di-lower alkylamino, lower aliphatic acylamino, cyano or nitro; and